Skip Navigation
ChemIDplus Lite•Browse•Advanced

Substance Name: Ticlopidine hydrochloride [USAN:USP:JAN]
RN: 53885-35-1
UNII: A1L4914FMF
InChIKey: MTKNGOHFNXIVOS-UHFFFAOYSA-N

Note

  • Ticlopidine is an effective inhibitor of platelet aggregation. The drug has been found to significantly reduce infarction size in acute myocardial infarcts and is an effective antithrombotic agent in arteriovenous fistulas, aorto-coronary bypass grafts, ischemic heart disease, venous thrombosis, and arteriosclerosis.

Molecular Formula

  • C14-H14-Cl-N-S.Cl-H

Molecular Weight

  • 300.2515
 

Classification Codes

  • Drug / Therapeutic Agent
  • Human Data
  • Inhibitor (Platelet)
  • Reproductive Effect

Names and Synonyms

Name of Substance

  • Ticlopidine hydrochloride [USAN:USP:JAN]

Synonyms

  • 4-C-32
  • 5-(o-Chlorobenzyl)-4,5,6,7-tetrahydrothieno-(3,2-c)pyridine hydrochloride
  • 53-32C
  • EINECS 258-837-4
  • Panaldine
  • Ticlid
  • Ticlodix
  • Ticlodone
  • Ticlopidine HCl
  • Ticlopidine hydrochloride
  • Tiklid
  • UNII-A1L4914FMF

Systematic Names

  • 5-(o-Chlorobenzyl)-4,5,6,7-tetrahydrothieno(3,2-c)pyridinium chloride
  • Thieno(3,2-c)pyridine, 4,5,6,7-tetrahydro-5-(o-chlorobenzyl)-, hydrochloride
  • Thieno(3,2-c)pyridine, 5-((2-chlorophenyl)methyl)-4,5,6,7-tetrahydro-, hydrochloride

Registry Numbers

CAS Registry Number

  • 53885-35-1

FDA UNII

  • A1L4914FMF

System Generated Number

  • 0053885351

Molecular Formulas

Molecular Formula

  • C14-H14-Cl-N-S.Cl-H

Molecular Formula Fragments

  • C14-H14-Cl-N-S
  • Cl-H
  • COMPONENT

Structure Descriptors

InChI

InChI=1S/C14H14ClNS.ClH/c15-13-4-2-1-3-11(13)9-16-7-5-14-12(10-16)6-8-17-14;/h1-4,6,8H,5,7,9-10H2;1H

InChIKey

MTKNGOHFNXIVOS-UHFFFAOYSA-N

Smiles

Cl.Clc1ccccc1CN2CCc3sccc3C2

Toxicity

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
monkey LD50 intraperitoneal 500mg/kg (500mg/kg)   New Drugs Annual: Cardiovascular Drugs. Vol. 1, Pg. 295, 1983.
mouse LD50 intravenous 55mg/kg (55mg/kg)   United States Patent Document. Vol. #4051141,
mouse LD50 oral 600mg/kg (600mg/kg)   Medical Pharmacy. Vol. 15, Pg. 272, 1981.
mouse LD50 subcutaneous 2690mg/kg (2690mg/kg)   Medical Pharmacy. Vol. 15, Pg. 272, 1981.
rat LD50 intravenous 70mg/kg (70mg/kg)   Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 12, Pg. 1204, 1981.
rat LD50 oral 1780mg/kg (1780mg/kg)   Medical Pharmacy. Vol. 15, Pg. 272, 1981.
rat LD50 subcutaneous > 3gm/kg (3000mg/kg) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)

LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES		 Yakkyoku. Pharmacy. Vol. 32, Pg. 1499, 1981.
women LDLo unreported 180mg/kg/18D- (180mg/kg) BLOOD: APLASTIC ANEMIA

LIVER: LIVER FUNCTION TESTS IMPAIRED

SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE"		 American Journal of Hematology. Vol. 59, Pg. 260, 1998.
women TDLo oral 49mg/kg/1W-I (49mg/kg) LIVER: LIVER FUNCTION TESTS IMPAIRED

LIVER: "JAUNDICE, CHOLESTATIC"		 American Journal of Hospital Pharmacy. Vol. 51, Pg. 1821, 1994.
women TDLo oral 189mg/kg/17D- (189mg/kg) LIVER: "JAUNDICE, CHOLESTATIC"

LIVER: LIVER FUNCTION TESTS IMPAIRED		 American Journal of Hospital Pharmacy. Vol. 51, Pg. 1821, 1994.
women TDLo oral 1896mg/kg/26W (1896mg/kg) GASTROINTESTINAL: NAUSEA OR VOMITING

LIVER: "JAUNDICE, CHOLESTATIC"		 Clinical Pharmacy. Vol. 12, Pg. 398, 1993.